Compositions and methods for treating seizure disorders
US-2018092864-A1 · Apr 5, 2018 · US
Use of serotonin 5-HT1A receptor agonists to treat diseases associated with sudden unexpected death in epilepsy
US11974992B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11974992-B2 |
| Application number | US-202217586477-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 27, 2022 |
| Priority date | Jan 26, 2022 |
| Publication date | May 7, 2024 |
| Grant date | May 7, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present application concerns the treatment and prevention of diseases associated with an increased risk of sudden unexpected death in epilepsy, such as Fragile X syndrome, by administering a selective 5-HT1A receptor agonist.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treatment of seizures in a patient exhibiting a FMR1 gene dysfunction and suffering from a disease with which Sudden Unexpected Death in Epilepsy (SUDEP) occurs, the method comprising administering a therapeutically effective amount of NLX-101 (also known as F-15599) having formula (IA): or a pharmaceutically acceptable salt thereof. 2. The method of claim 1 , wherein said disease with which SUDEP occurs is Fragile X syndrome. 3. A method of treating Fragile X syndrome in a patient exhibiting a FMR1 gene dysfunction, the method comprising administering to the patient a therapeutically effective amount of NLX-101 (also known as F-15599) having formula (IA): or a pharmaceutically acceptable salt thereof.
Assignees
Inventors
Classifications
Antiepileptics; Anticonvulsants · CPC title
Drugs for disorders of the respiratory system · CPC title
containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine · CPC title
Non condensed piperidines, e.g. piperocaine · CPC title
- A61K31/4427Primary
containing further heterocyclic ring systems · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11974992B2 cover?
- The present application concerns the treatment and prevention of diseases associated with an increased risk of sudden unexpected death in epilepsy, such as Fragile X syndrome, by administering a selective 5-HT1A receptor agonist.
- Who is the assignee on this patent?
- Neurolixis, Univ California
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4427. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).